Last reviewed · How we verify
Hepatitis A (control)
Hepatitis A (control) is a inactivated viral vaccine Biologic drug developed by International Vaccine Institute. It is currently FDA-approved for Prevention of hepatitis A virus infection in susceptible populations.
This inactivated hepatitis A vaccine stimulates the immune system to produce antibodies against hepatitis A virus, providing protective immunity against infection.
Hepatitis A is a viral infection that can be prevented through vaccination, with vaccines available for other conditions such as Condylomata Acuminata, Chickenpox, Dengue Fever, Dengue Hemorrhagic Fever, and Influenza Human. Hepatitis A vaccines do not exist in the provided information, but Hepatitis B vaccines, which are binding agents that target the surface antigen (HBsAg), are available for other conditions.
At a glance
| Generic name | Hepatitis A (control) |
|---|---|
| Sponsor | International Vaccine Institute |
| Drug class | inactivated viral vaccine |
| Target | Hepatitis A virus surface antigens |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains inactivated (killed) hepatitis A virus particles that trigger both humoral and cellular immune responses. Upon vaccination, the body produces specific antibodies (primarily IgG) that neutralize the virus and provide long-term protection against hepatitis A infection. This is a control vaccine used as a reference standard in clinical trials.
Approved indications
- Prevention of hepatitis A virus infection in susceptible populations
Common side effects
- Injection site soreness or erythema
- Headache
- Fatigue
- Myalgia
- Low-grade fever
Key clinical trials
- A Study to Assess Efficacy and Safety of HH-003 Injection in Subjects With Chronic Hepatitis Delta Virus Infection (PHASE2)
- Oral-Periodontal Evaluation and Assessment of Oral Fluid Biomarkers in Patients With Hepatitis B+D
- Fungal Infection Susceptibility
- SGLT2i to Prevent of Liver Complications in Patients With CHB and Diabetes Mellitus (PHASE4)
- Effect of Fufang Biejiaruangan Combined With Antiviral Therapy on the Incidence of Hepatocellular Carcinoma in Patients With Hepatitis B-related Cirrhosis: A Multicenter, Randomized, Placebo-controlled Study (NA)
- A Study to Assess the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 in Participants With Chronic Hepatitis B Virus Infection (PHASE1)
- A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M (PHASE2)
- A Study on IB-001 Dose Response and Tolerability in Healthy Adults and Those With Chronic Hepatitis B (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hepatitis A (control) CI brief — competitive landscape report
- Hepatitis A (control) updates RSS · CI watch RSS
- International Vaccine Institute portfolio CI
Frequently asked questions about Hepatitis A (control)
What is Hepatitis A (control)?
How does Hepatitis A (control) work?
What is Hepatitis A (control) used for?
Who makes Hepatitis A (control)?
What drug class is Hepatitis A (control) in?
What development phase is Hepatitis A (control) in?
What are the side effects of Hepatitis A (control)?
What does Hepatitis A (control) target?
Related
- Drug class: All inactivated viral vaccine drugs
- Target: All drugs targeting Hepatitis A virus surface antigens
- Manufacturer: International Vaccine Institute — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease
- Indication: Drugs for Prevention of hepatitis A virus infection in susceptible populations
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing